HV
About
hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker ‘HVO’).
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 8,972 investors are based in London, England, United Kingdom.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- London, UK
Find more investors like hVIVO
Search Investors